<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Post <z:hpo ids='HP_0001297'>stroke</z:hpo> <z:hpo ids='HP_0000726'>dementia</z:hpo> (PSD) develops in up to 40% of patients and often co-exists with <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> in the elderly </plain></SENT>
<SENT sid="1" pm="."><plain>Unsurprisingly, the combination of <z:hpo ids='HP_0001297'>stroke</z:hpo> and <z:hpo ids='HP_0000726'>dementia</z:hpo> is associated with considerable morbidity and mortality, and is devastating to patients and carers </plain></SENT>
<SENT sid="2" pm="."><plain>Limited trial evidence suggests that lowering <z:mp ids='MP_0002842'>high blood pressure</z:mp> reduces the development of <z:hpo ids='HP_0001268'>cognitive decline</z:hpo>, vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> and PSD, although whether this relates to the magnitude of BP reduction or specific drug classes remains unclear </plain></SENT>
<SENT sid="3" pm="."><plain>Biological plausibility and/or existing studies suggest that other types of drug treatments might also be effective, including <z:chebi fb="3" ids="15354">choline</z:chebi> esterase inhibitors, <z:chebi fb="23" ids="18059">lipid</z:chebi> lowering agents, antiplatelet agents, and selective <z:chebi fb="19" ids="28790">serotonin</z:chebi> reuptake inhibitors </plain></SENT>
<SENT sid="4" pm="."><plain>Preventing <z:hpo ids='HP_0001268'>cognitive decline</z:hpo> and <z:hpo ids='HP_0000726'>dementia</z:hpo> post <z:hpo ids='HP_0001297'>stroke</z:hpo> is critical and large definitive trials are now needed </plain></SENT>
</text></document>